ABT RSI Chart
Last 7 days
-1.3%
Last 30 days
-5.1%
Last 90 days
-6.7%
Trailing 12 Months
-4.8%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2024 | 40.3B | 0 | 0 | 0 |
2023 | 41.5B | 40.2B | 40.0B | 40.1B |
2022 | 44.5B | 45.5B | 45.0B | 43.7B |
2021 | 37.3B | 40.2B | 42.3B | 43.1B |
2020 | 32.1B | 31.4B | 32.2B | 34.6B |
2019 | 30.7B | 30.9B | 31.4B | 31.9B |
2018 | 28.4B | 29.6B | 30.4B | 30.6B |
2017 | 22.3B | 23.6B | 25.1B | 27.4B |
2016 | 20.4B | 20.6B | 20.7B | 20.9B |
2015 | 20.4B | 20.5B | 20.6B | 20.4B |
2014 | 19.6B | 19.7B | 20.0B | 20.2B |
2013 | 21.1B | 20.7B | 20.2B | 19.7B |
2012 | 35.1B | 30.8B | 26.2B | 21.5B |
2011 | 36.5B | 37.3B | 38.4B | 38.9B |
2010 | 31.7B | 33.1B | 34.0B | 35.2B |
2009 | 29.5B | 29.7B | 29.9B | 30.8B |
2008 | 26.8B | 27.7B | 28.6B | 29.5B |
2007 | 0 | 0 | 0 | 25.9B |
Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index
Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.
Returns of $10,000 invested in:
Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022
Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
May 07, 2024 | earnhardt lisa d | sold | -2,428,120 | 106 | -22,852 | executive vice president |
Apr 26, 2024 | mcdew darren w | acquired | - | - | 1,866 | - |
Apr 26, 2024 | roman michael f | acquired | - | - | 1,866 | - |
Apr 26, 2024 | babineaux-fontenot claire | acquired | - | - | 1,866 | - |
Apr 26, 2024 | blount sally e. | acquired | - | - | 1,866 | - |
Apr 26, 2024 | o'grady michael | acquired | - | - | 1,866 | - |
Apr 26, 2024 | gonzalez patricia paola | acquired | - | - | 1,866 | - |
Apr 26, 2024 | alpern robert j | acquired | - | - | 1,866 | - |
Apr 26, 2024 | starks daniel j | acquired | - | - | 1,866 | - |
Apr 26, 2024 | kumbier michelle | acquired | - | - | 1,866 | - |
Which funds bought or sold ABT recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 08, 2024 | Heritage Wealth Advisors | reduced | -2.78 | 4,651 | 1,222,410 | 0.06% |
May 08, 2024 | BNP PARIBAS ASSET MANAGEMENT Holding S.A. | added | 2.48 | 2,076,000 | 37,716,000 | 0.10% |
May 08, 2024 | STEVENS CAPITAL MANAGEMENT LP | added | 68.77 | 859,000 | 2,015,000 | 0.39% |
May 08, 2024 | Crestwood Advisors Group, LLC | added | 10.97 | 1,284,480 | 10,089,900 | 0.22% |
May 08, 2024 | SECTOR GAMMA AS | sold off | -100 | -4,389,150 | - | -% |
May 08, 2024 | Texas Yale Capital Corp. | added | 1.54 | 65,914 | 1,424,730 | 0.06% |
May 08, 2024 | SHAYNE & JACOBS, LLC | unchanged | - | 10,052 | 318,248 | 0.09% |
May 08, 2024 | TAURUS ASSET MANAGEMENT, LLC | reduced | -6.37 | -47,009 | 1,369,260 | 0.14% |
May 08, 2024 | Columbia Asset Management | unchanged | - | - | 621,000 | 0.13% |
May 08, 2024 | PROFUND ADVISORS LLC | reduced | -10.54 | -248,959 | 3,018,470 | 0.12% |
Unveiling Abbott Laboratories's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to Abbott Laboratories)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
ABT | 182.1B | 40.3B | 32.37 | 4.52 | ||||
BDX | 67.9B | 19.7B | 50.95 | 3.44 | ||||
ALGN | 21.1B | 3.9B | 45.69 | 5.39 | ||||
BAX | 18.3B | 14.9B | 6.92 | 1.23 | ||||
MID-CAP | ||||||||
ATR | 9.9B | 3.5B | 31.57 | 2.79 | ||||
HSIC | 9.4B | 12.5B | 24.22 | 0.75 | ||||
BIO | 7.9B | 2.6B | -24.54 | 3.04 | ||||
XRAY | 5.9B | 3.9B | -62.67 | 1.49 | ||||
AXNX | 3.4B | 387.1M | -215.88 | 8.88 | ||||
PDCO | 2.4B | 6.6B | 12.18 | 0.36 | ||||
SMALL-CAP | ||||||||
AHCO | 1.2B | 3.2B | -1.75 | 0.38 | ||||
ANIK | 374.6M | 169.3M | -4.88 | 2.21 | ||||
ANGO | 244.7M | 324.0M | -1.27 | 0.76 | ||||
APYX | 59.9M | 52.3M | -3.2 | 1.14 | ||||
AEMD | 3.1M | 3.7M | -0.25 | 0.82 |
Abbott Laboratories News
Income Statement (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | -2.7% | 9,964 | 10,241 | 10,143 | 9,978 | 9,747 | 10,091 | 10,410 | 11,257 | 11,895 | 11,468 | 10,928 | 10,223 | 10,456 | 10,701 | 8,853 | 7,328 | 7,726 | 8,314 | 8,076 | 7,979 | 7,535 |
Costs and Expenses | 1.4% | 8,578 | 8,461 | 8,496 | 8,436 | 8,238 | 8,787 | 8,640 | 8,881 | 8,983 | 9,090 | 8,382 | 8,831 | 8,347 | 8,269 | 7,358 | 6,656 | 6,968 | 6,925 | 6,878 | 6,773 | 6,796 |
S&GA Expenses | 8.6% | 2,959 | 2,724 | 2,723 | 2,740 | 2,762 | 2,973 | 2,731 | 2,757 | 2,787 | 3,048 | 2,767 | 2,726 | 2,783 | 2,570 | 2,302 | 2,276 | 2,548 | 2,413 | 2,440 | 2,434 | 2,478 |
R&D Expenses | -2.3% | 684 | 700 | 672 | 715 | 654 | 725 | 782 | 684 | 697 | 762 | 672 | 654 | 654 | 698 | 580 | 564 | 578 | 595 | 596 | 577 | 672 |
EBITDA Margin | -2.1% | 0.21* | 0.21* | 0.20* | 0.20* | 0.21* | 0.23* | 0.25* | 0.26* | 0.25* | 0.24* | 0.24* | 0.23* | 0.22* | 0.19* | 0.17* | 0.16* | 0.18* | 0.18* | 0.18* | - | - |
Interest Expenses | -11.3% | 141 | 159 | 166 | 159 | 153 | 154 | 141 | 132 | 131 | 131 | 133 | 134 | 135 | 136 | 137 | 134 | 139 | 164 | 167 | 168 | 171 |
Income Taxes | 5.0% | 211 | 201 | 235 | 261 | 244 | 287 | 323 | 334 | 429 | 338 | 393 | 159 | 250 | 230 | 189 | -11.00 | 89.00 | 191 | 143 | 96.00 | -40.00 |
Earnings Before Taxes | -20.0% | 1,436 | 1,795 | 1,671 | 1,636 | 1,562 | 1,320 | 1,758 | 2,352 | 2,876 | 2,327 | 2,493 | 1,348 | 2,043 | 2,388 | 1,421 | 526 | 633 | 1,240 | 1,103 | 1,102 | 632 |
EBT Margin | -2.4% | 0.16* | 0.17* | 0.15* | 0.16* | 0.17* | 0.19* | 0.21* | 0.22* | 0.20* | 0.19* | 0.20* | 0.18* | 0.17* | 0.14* | 0.12* | 0.11* | 0.13* | 0.13* | 0.12* | - | - |
Net Income | -23.5% | 1,220 | 1,594 | 1,436 | 1,375 | 1,318 | 1,033 | 1,435 | 2,018 | 2,447 | 1,989 | 2,100 | 1,189 | 1,793 | 2,162 | 1,232 | 537 | 564 | 1,049 | 960 | 1,006 | 672 |
Net Income Margin | -2.2% | 0.14* | 0.14* | 0.13* | 0.13* | 0.14* | 0.16* | 0.18* | 0.19* | 0.17* | 0.16* | 0.17* | 0.16* | 0.15* | 0.13* | 0.10* | 0.10* | 0.11* | 0.12* | 0.10* | - | - |
Free Cashflow | -72.5% | 627 | 2,283 | 1,317 | 696 | 763 | 1,716 | 2,313 | 2,031 | 1,744 | 2,453 | 2,240 | 1,715 | 2,240 | 3,119 | 1,570 | 680 | 355 | 1,982 | 1,547 | - | - |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -1.0% | 72,467 | 73,214 | 72,090 | 73,354 | 73,794 | 74,438 | 72,801 | 74,202 | 74,007 | 21,174 | 73,795 | 73,269 | 72,785 | 20,955 | 69,043 | 68,776 | 66,777 | 18,007 | 68,539 | 68,427 | 67,610 |
Current Assets | -1.3% | 22,376 | 22,670 | 22,664 | 23,505 | 24,377 | 25,224 | 24,845 | 24,956 | 23,429 | 24,239 | 23,492 | 22,627 | 21,817 | 20,441 | 17,390 | 17,221 | 15,498 | 15,667 | 16,119 | 15,195 | 14,409 |
Cash Equivalents | -8.9% | 6,284 | 6,896 | 6,709 | 7,835 | 9,161 | 9,882 | 9,594 | 8,937 | 7,675 | 9,799 | 9,302 | 8,658 | 8,054 | 6,838 | 4,480 | 4,763 | 3,377 | 3,860 | 4,091 | 3,137 | 3,022 |
Inventory | 3.9% | 6,827 | 6,570 | 6,650 | 6,871 | 6,673 | 6,173 | 5,734 | 5,899 | 5,691 | 5,157 | 5,261 | 5,439 | 5,387 | 5,012 | 5,152 | 5,202 | 4,568 | 4,316 | 4,392 | 4,352 | 4,085 |
Net PPE | -0.5% | 10,107 | 10,154 | 9,552 | 9,449 | 9,282 | 9,162 | 8,689 | 8,818 | 8,908 | 8,959 | 8,831 | 8,816 | 8,832 | 9,029 | 8,620 | 8,343 | 7,907 | 8,038 | 7,825 | 7,825 | 7,626 |
Goodwill | -1.2% | 23,400 | 23,679 | 23,300 | 23,300 | 22,927 | 22,799 | 22,284 | 22,744 | 23,179 | 23,200 | 23,300 | 23,500 | 23,384 | 23,700 | 23,300 | 23,100 | 22,927 | 23,200 | 23,046 | 23,329 | 23,209 |
Current Liabilities | 1.3% | 14,021 | 13,841 | 13,042 | 14,350 | 14,530 | 15,489 | 13,365 | 12,392 | 12,647 | 13,105 | 12,867 | 12,614 | 12,462 | 11,907 | 10,257 | 10,959 | 10,808 | 10,863 | 10,491 | 9,062 | 9,113 |
Short Term Borrowings | - | - | - | - | - | - | - | - | - | - | - | 197 | 199 | 199 | 213 | 208 | 205 | 204 | 201 | 204 | 204 | 201 |
Long Term Debt | -7.5% | 12,576 | 13,599 | 14,477 | 14,562 | 14,615 | 14,522 | 15,297 | 16,755 | 17,086 | 17,296 | 17,446 | 17,547 | 17,489 | 18,527 | 18,349 | 18,184 | 16,804 | 16,661 | 17,639 | 18,982 | 18,845 |
LT Debt, Current | 86.1% | 2,010 | 1,080 | 1,051 | 2,284 | 2,285 | 2,251 | 1,117 | 5.00 | 4.00 | 754 | 754 | 755 | 756 | 7.00 | 6.00 | 1,290 | 1,264 | 1,277 | 1,254 | 8.00 | 8.00 |
LT Debt, Non Current | -100.0% | - | 13,599 | 14,477 | 14,562 | 14,615 | 14,522 | 15,297 | 16,755 | 17,086 | 17,296 | 17,446 | 17,547 | 17,489 | 18,527 | 18,349 | 18,184 | 16,804 | 16,661 | 17,639 | 18,982 | 18,845 |
Shareholder's Equity | 1.1% | 39,043 | 38,603 | 37,481 | 72.00 | 37,010 | 36,686 | 35,675 | 108 | 79.00 | 135 | 41.00 | 33,800 | 33,562 | 24,145 | 31,386 | 79.00 | 165 | 31,088 | 60.00 | 31,686 | 23.00 |
Retained Earnings | 1.2% | 38,011 | 37,554 | 36,920 | 36,355 | 35,868 | 35,257 | 35,115 | 34,487 | 33,295 | 31,528 | 30,376 | 29,053 | 28,669 | 27,627 | 26,266 | 25,669 | 25,786 | 25,847 | 25,440 | 25,045 | 24,613 |
Accumulated Depreciation | 1.4% | 11,948 | 11,779 | 11,559 | 11,477 | 11,323 | 11,050 | 10,617 | 10,640 | 10,613 | 10,405 | 10,351 | 10,258 | 9,865 | 9,764 | 9,352 | 9,031 | 8,800 | 8,761 | 8,518 | 8,506 | 8,279 |
Shares Outstanding | 0.0% | 1,740 | 1,740 | 1,740 | 1,740 | 1,742 | 1,753 | 1,756 | 1,758 | 1,762 | 1,775 | 1,775 | 1,779 | 1,777 | 1,773 | 1,774 | 1,771 | 1,769 | 1,768 | 1,768 | - | - |
Minority Interest | 4.0% | 233 | 224 | 213 | 230 | 222 | 219 | 209 | 226 | 230 | 222 | 216 | 229 | 226 | 219 | 209 | 220 | 209 | 213 | 202 | 208 | 204 |
Float | - | - | - | - | 185,171 | - | - | - | 186,105 | - | - | - | 200,631 | - | - | - | 157,957 | - | - | - | 144,957 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -66.3% | 1,025 | 3,038 | 1,877 | 1,203 | 1,143 | 2,326 | 2,780 | 2,410 | 2,065 | 3,067 | 2,701 | 2,128 | 2,637 | 3,798 | 2,066 | 1,322 | 715 | 2,416 | 1,948 | 1,060 | 712 |
Share Based Compensation | 166.7% | 304 | 114 | 117 | 132 | 281 | 115 | 123 | 142 | 305 | 106 | 114 | 132 | 288 | 98.00 | 100 | 115 | 233 | 85.00 | 94.00 | 114 | 226 |
Cashflow From Investing | 48.4% | -425 | -824 | -634 | -1,213 | -462 | -632 | -484 | -264 | -360 | -671 | -651 | -264 | -422 | -731 | -472 | -619 | -393 | -489 | -432 | -498 | -396 |
Cashflow From Financing | 42.7% | -1,176 | -2,052 | -2,340 | -1,289 | -1,410 | -1,457 | -1,543 | -813 | -3,823 | -1,886 | -1,377 | -1,264 | -967 | -787 | -1,915 | 658 | -735 | -2,185 | -513 | -449 | -1,142 |
Dividend Payments | -100.0% | - | 888 | 888 | 890 | 890 | 823 | 826 | 828 | 832 | 798 | 801 | 803 | 800 | 641 | 639 | 642 | 638 | 568 | 569 | 568 | 565 |
Buy Backs | -12.7% | 226 | 259 | 2.00 | 426 | 540 | 685 | 798 | 5.00 | 2,307 | 974 | 579 | 471 | 275 | 161 | 2.00 | 4.00 | 236 | 496 | 1.00 | 4.00 | 217 |
Condensed Consolidated Statement of Earnings (Unaudited) - USD ($) shares in Thousands, $ in Millions | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Income Statement [Abstract] | ||
Net sales | $ 9,964 | $ 9,747 |
Cost of products sold, excluding amortization of intangible assets | 4,463 | 4,331 |
Amortization of intangible assets | 472 | 491 |
Research and development | 684 | 654 |
Selling, general and administrative | 2,959 | 2,762 |
Total operating cost and expenses | 8,578 | 8,238 |
Operating earnings | 1,386 | 1,509 |
Interest expense | 141 | 153 |
Interest (income) | (80) | (101) |
Net foreign exchange (gain) loss | 0 | 6 |
Other (income) expense, net | (111) | (111) |
Earnings before taxes | 1,436 | 1,562 |
Taxes on earnings | 211 | 244 |
Net Earnings | $ 1,225 | $ 1,318 |
Basic Earnings Per Common Share (in dollars per share) | $ 0.70 | $ 0.75 |
Diluted Earnings Per Common Share (in dollars per share) | $ 0.70 | $ 0.75 |
Average Number of Common Shares Outstanding Used for Basic Earnings Per Common Share (in shares) | 1,740,203 | 1,741,738 |
Dilutive Common Stock Options (in shares) | 9,449 | 9,977 |
Average Number of Common Shares Outstanding Plus Dilutive Common Stock Options (in shares) | 1,749,652 | 1,751,715 |
Outstanding Common Stock Options Having No Dilutive Effect (in shares) | 6,892 | 7,332 |
Condensed Consolidated Balance Sheet (Unaudited) - USD ($) $ in Millions | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current Assets: | ||
Cash and cash equivalents | $ 6,284 | $ 6,896 |
Short-term investments | 367 | 383 |
Trade receivables, less allowances of $439 in 2024 and $444 in 2023 | 6,605 | 6,565 |
Inventories: | ||
Finished products | 4,063 | 3,946 |
Work in process | 881 | 807 |
Materials | 1,883 | 1,817 |
Total inventories | 6,827 | 6,570 |
Prepaid expenses and other receivables | 2,293 | 2,256 |
Total Current Assets | 22,376 | 22,670 |
Investments | 818 | 799 |
Property and equipment, at cost | 22,055 | 21,933 |
Less: accumulated depreciation and amortization | 11,948 | 11,779 |
Net property and equipment | 10,107 | 10,154 |
Intangible assets, net of amortization | 8,296 | 8,815 |
Goodwill | 23,383 | 23,679 |
Deferred income taxes and other assets | 7,487 | 7,097 |
Total Assets | 72,467 | 73,214 |
Current Liabilities: | ||
Trade accounts payable | 4,178 | 4,295 |
Salaries, wages and commissions | 1,092 | 1,597 |
Other accrued liabilities | 5,220 | 5,422 |
Dividends payable | 959 | 955 |
Income taxes payable | 562 | 492 |
Current portion of long-term debt | 2,010 | 1,080 |
Total Current Liabilities | 14,021 | 13,841 |
Long-term debt | 12,576 | 13,599 |
Post-employment obligations, deferred income taxes and other long-term liabilities | 6,827 | 6,947 |
Commitments and Contingencies | ||
Shareholders’ Investment: | ||
Preferred shares, one dollar par value Authorized — 1,000,000 shares, none issued | 0 | 0 |
Common shares, without par value Authorized — 2,400,000,000 shares Issued at stated capital amount — Shares: 2024: 1,989,789,999; 2023: 1,987,883,852 | 24,726 | 24,869 |
Common shares held in treasury, at cost — Shares: 2024: 250,155,515; 2023: 253,807,494 | (15,761) | (15,981) |
Earnings employed in the business | 38,011 | 37,554 |
Accumulated other comprehensive income (loss) | (8,166) | (7,839) |
Total Abbott Shareholders’ Investment | 38,810 | 38,603 |
Noncontrolling Interests in Subsidiaries | 233 | 224 |
Total Shareholders’ Investment | 39,043 | 38,827 |
Total Liabilities and Shareholders' Investment | $ 72,467 | $ 73,214 |